IONS stock forecast, quote, news & analysis
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs... Show more
Why Ionis Pharmaceuticals (IONS) Stock Is Down -35.7% in the Last 30 Days
Key Takeaways
- Ionis Pharmaceuticals (IONS) shares have fallen about 35.7% over the past 30 days, from a closing price of $42.70 on October 14, 2026, to $27.44 in recent trading.
- The sharpest decline followed the November 9, 2026 third-quarter report, when the company cut its full-year 2026 TRYNGOLZA sales guidance to roughly $50 million from a prior range of $100–$110 million.
- Ionis beat third-quarter revenue expectations and reaffirmed its total 2026 revenue guidance, but the slower-than-expected TRYNGOLZA launch overshadowed otherwise solid headline results.
- DAWNZERA (donidalorsen) continued to grow, generating $37 million in third-quarter U.S. net product sales, and the company maintained its full-year DAWNZERA guidance of $110–$120 million.
- Over the past quarter, the stock has declined roughly 51% from levels near $55 in mid-August, pressured by both commercial and partner-pipeline setbacks.
- For additional context, investors can review detailed Price Targets, Earnings, and Forecast information for IONS.
- Readers can also explore Trending AI Robots for automated trading strategies across the market.
Ionis Pharmaceuticals (IONS) Company Overview and Market Position
Ionis Pharmaceuticals, Inc. is a commercial and clinical-stage biotechnology company specializing in RNA-targeted therapeutics. Its wholly owned commercial portfolio includes TRYNGOLZA (olezarsen) for familial chylomicronemia syndrome and severe hypertriglyceridemia, DAWNZERA (donidalorsen) for hereditary angioedema, and ZANVASTRO (zilganersen) for Alexander disease. Through partnerships with companies such as Novartis (NVS) and GSK (GSK), Ionis also advances a broad pipeline of investigational therapies across cardiovascular, neurological, and rare diseases. Investors follow the stock closely because its commercial launch execution and late-stage pipeline readouts can drive substantial valuation swings.
Ionis Pharmaceuticals (IONS) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, IONS declined from a closing price of $42.70 on October 14, 2026, to $27.44 in recent trading, a drop of approximately 35.7%. The move was concentrated in the first full week of November, when the stock fell from $39.42 on November 6 to a close of $31.00 on November 9, a single-session decline of 21.4%, before continuing lower.
The quarterly picture is even steeper. From a closing level of about $55.87 in mid-August, shares have lost roughly 51% over the last three months. The stock reached levels above $63 in late August before a sustained decline through September, October, and early November, reflecting a combination of pipeline disappointments and growing concerns about commercial execution.
What Drove IONS Stock Price in the Last 30 Days
The primary catalyst was the November 9, 2026 third-quarter earnings announcement. Ionis reported third-quarter total revenue of approximately $242.7 million, up about 55% year over year and ahead of consensus estimates, and reaffirmed full-year 2026 total revenue guidance of $875–$900 million. However, the company sharply reduced its 2026 TRYNGOLZA product sales outlook to roughly $50 million, down from $100–$110 million, citing a more gradual launch ramp than anticipated in severe hypertriglyceridemia. Third-quarter TRYNGOLZA sales were just $9 million, and management acknowledged that building a new treatment market was taking longer than expected. The guidance cut triggered a 21.4% single-day drop on heavy volume and prompted multiple securities-investigation notices from shareholder-focused law firms.
Compounding the selloff, reports emerged on November 7 that Novartis was largely abandoning development of pelacarsen, a partnered cardiovascular therapy discovered by Ionis, following a late-stage trial setback. Together, the TRYNGOLZA guidance reduction and renewed scrutiny of the partner pipeline drove the stock to multi-month lows.
What Drove IONS Stock Performance Over the Last Quarter
The broader three-month decline reflects a shift from optimism around Ionis's first large-market commercial launches to concerns about execution. In August, the CARDIO-TTRansform study of eplontersen missed its primary composite endpoint in the overall population, and pelacarsen's Phase 3 outcomes in Lp(a) were negative, ultimately leading Novartis to step back from the program. Although Ionis reported positive Phase 3 results for sefaxersen in IgA nephropathy and ulefnersen in FUS-ALS during October, these pipeline wins were not enough to offset fading confidence in the TRYNGOLZA launch. The company also moved its timeline for sustained positive cash flow from 2028 to 2029, reinforcing investor concerns about near-term profitability.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots. Tickeron operates hundreds of automated bots that trade thousands of tickers, but only the top-performing and most relevant strategies appear in this section. Each bot follows its own approach, timeframe, and performance metrics, allowing traders to compare different styles of algorithmic decision-making. The page is designed to help users identify actively traded strategies rather than manually screening the full bot marketplace. Investors interested in systematic, data-driven approaches to market participation can browse the curated list to see which bots are currently attracting attention.
IONS Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the key factor for IONS will be whether TRYNGOLZA's launch trajectory improves as prescribing deepens and payer coverage expands. Management has outlined execution priorities, including broadening the prescriber base and improving reimbursement, and has pointed to 2027 as a critical year for the product. Investors will also monitor DAWNZERA's continued growth and the initial uptake of ZANVASTRO. On the pipeline side, upcoming catalysts include data from the Angelman syndrome program and further progress on sefaxersen and ulefnersen as results are shared with regulators. Macroeconomic conditions, competitive dynamics in the rare-disease and cardiometabolic markets, and any updates to financial guidance will also influence sentiment. These are forward-looking considerations, not investment recommendations.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
IONS in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 09, 2026
IONS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 29 of 35 cases where IONS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where IONS advanced for three days, in 190 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IONS as a result. In 73 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.
The Moving Average Convergence Divergence Histogram (MACD) for IONS turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 31 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 63%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IONS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
The Aroon Indicator for IONS entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.898) is normal, around the industry mean (3.498). P/E Ratio (-11.328) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (4.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (8.368) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. IONS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IONS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What is a straddle?
Tickeron Innovates Profitable Trading with AI-Based Trend Prediction Engine (TPE)
What are the key differences between VFIAX and SPY, and how do they compare as investment options?
What are the key characteristics that help traders recognize a rising wedge pattern?
Best Metal Stocks: A Glimpse into the Backbone of Modern Infrastructure
General Information
a developer of antisense drugs
Industry Biotechnology